.jpg)
Rhythm eyes label expansion after Imcivree helps patients with brain damage-related obesity lose weight
Rhythm's Imcivree helped patients with obesity due to brain damage lose weight in a phase 3 study. With the trial win, the company is planning regulatory filings for what could be the first therapy approved in the rare disease population.
Rhythm's Imcivree helped patients with obesity due to brain damage lose weight in a phase 3 study. With the trial win, the company is planning regulatory filings for what could be the first therapy approved in the rare disease population.
